Uncategorized

Type 1 Diabetes (T1D) -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

Press Release

Type 1 Diabetes (T1D) Industry

Description

Wiseguyreports.Com Adds “Type 1 Diabetes (T1D) -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database

Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others.

While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.

The global Type 1 Diabetes (T1D) market is valued at 1960 million US$ in 2018 and will reach 2810 million US$ by the end of 2025, growing at a CAGR of 4.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Type 1 Diabetes (T1D) market based on company, product type, end user and key regions.

This report studies the global market size of Type 1 Diabetes (T1D) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Type 1 Diabetes (T1D) in these regions.

This research report categorizes the global Type 1 Diabetes (T1D) market by top players/brands, region, type and end user. This report also studies the global Type 1 Diabetes (T1D) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/4119950-global-type-1-diabetes-t1d-market-insights-forecast-to-2025

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Novo Nordisk 
Sanofi 
Eli Lilly 
Merck 
Boehringer Ingelheim 
Samsung Bioepis 
Biocon 
Astellas 
Janssen 
Bristol-Myers Squibb 
Lexicon 
Sanofi

Market size by Product 
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs

Market size by End User 
Children
Adults

Market size by Region 
North America
United States
Canada
Mexico
Asia-Pacific
China
India

The study objectives of this report are: 
To study and analyze the global Type 1 Diabetes (T1D) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Type 1 Diabetes (T1D) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Type 1 Diabetes (T1D) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Type 1 Diabetes (T1D) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Leave a Query @ https://www.wiseguyreports.com/enquiry/4119950-global-type-1-diabetes-t1d-market-insights-forecast-to-2025

 

Table of Contents

1 Study Coverage
1.1 Type 1 Diabetes (T1D) Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Type 1 Diabetes (T1D) Market Size Growth Rate by Product
1.4.2 Rapid Acting Insulin Analogs
1.4.3 Long Acting Insulin Analogs
1.4.4 Premix Insulin Analogs
1.5 Market by End User
1.5.1 Global Type 1 Diabetes (T1D) Market Size Growth Rate by End User
1.5.2 Children
1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Type 1 Diabetes (T1D) Market Size
2.1.1 Global Type 1 Diabetes (T1D) Revenue 2014-2025
2.1.2 Global Type 1 Diabetes (T1D) Sales 2014-2025
2.2 Type 1 Diabetes (T1D) Growth Rate by Regions
2.2.1 Global Type 1 Diabetes (T1D) Sales by Regions
2.2.2 Global Type 1 Diabetes (T1D) Revenue by Regions

….

11 Company Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Company Business Overview
11.1.3 Novo Nordisk Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Novo Nordisk Type 1 Diabetes (T1D) Products Offered
11.1.5 Novo Nordisk Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Company Business Overview
11.2.3 Sanofi Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Sanofi Type 1 Diabetes (T1D) Products Offered
11.2.5 Sanofi Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Company Business Overview
11.3.3 Eli Lilly Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Eli Lilly Type 1 Diabetes (T1D) Products Offered
11.3.5 Eli Lilly Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Company Business Overview
11.4.3 Merck Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Merck Type 1 Diabetes (T1D) Products Offered
11.4.5 Merck Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Company Business Overview
11.5.3 Boehringer Ingelheim Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Boehringer Ingelheim Type 1 Diabetes (T1D) Products Offered
11.5.5 Boehringer Ingelheim Recent Development
11.6 Samsung Bioepis
11.6.1 Samsung Bioepis Company Details
11.6.2 Company Business Overview
11.6.3 Samsung Bioepis Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Samsung Bioepis Type 1 Diabetes (T1D) Products Offered
11.6.5 Samsung Bioepis Recent Development
11.7 Biocon
11.7.1 Biocon Company Details
11.7.2 Company Business Overview
11.7.3 Biocon Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Biocon Type 1 Diabetes (T1D) Products Offered
11.7.5 Biocon Recent Development
11.8 Astellas
11.8.1 Astellas Company Details
11.8.2 Company Business Overview
11.8.3 Astellas Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Astellas Type 1 Diabetes (T1D) Products Offered
11.8.5 Astellas Recent Development
11.9 Janssen
11.9.1 Janssen Company Details
11.9.2 Company Business Overview
11.9.3 Janssen Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Janssen Type 1 Diabetes (T1D) Products Offered
11.9.5 Janssen Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Company Business Overview
11.10.3 Bristol-Myers Squibb Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Bristol-Myers Squibb Type 1 Diabetes (T1D) Products Offered
11.10.5 Bristol-Myers Squibb Recent Development
11.11 Lexicon
11.12 Sanofi

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=4119950

Continued…            

 

Contact Us: [email protected] Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

 

 

Recent Comments

    RSS blogs